BACKGROUND: An in-depth study of neurological symptoms and complications of influenza in elderly patients. This population group is more susceptible to complications of the disease and these complications are more likely to end in death. METHODS: A retrospective analysis of patient data was performed. All patients aged 65 years and older were included in the study. The study period was from the 1st of January , 2018 to 31st of December, 2021. All symptoms and complications of influenza were analyzed. Especially neurological and general symptoms were analyzed. Data were extracted from the complete medical records of the patients. RESULTS: The most common symptoms of influenza in the elderly were fever in 218 cases (83.52%), cough in 189 patients (72.41%), general weakness in 182 (69.73%) and fatigue in 166 patients (63.6%). Myalgias were experienced by 106 patients (40.61%) and arthralgias by 101 patients (38.7%). Headache occurred in only 21 patients (8.06%). Encephalopathy was observed in 7 elderly patients (2.68%) during hospitalization. Influenza encephalitis was noted in 2 cases. CONCLUSION: The most common neurological symptoms of influenza in more than half of the elderly are general weakness and increased fatigue. Myalgias are common, headache less often. Nausea is not uncommon. Of the complications, encephalopathy is the most common. Cases of influenza encephalitis have also been reported. We have not encountered a stroke. Concerning other complications, bacterial pneumonia was the most common.
- MeSH
- bolesti hlavy etiologie epidemiologie MeSH
- chřipka lidská * komplikace epidemiologie MeSH
- horečka etiologie MeSH
- kašel etiologie MeSH
- lidé MeSH
- myalgie etiologie epidemiologie MeSH
- nemoci nervového systému epidemiologie etiologie MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- svalová slabost etiologie epidemiologie MeSH
- únava etiologie epidemiologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Influenza vaccination reduces the risk of adverse cardiovascular events.The IAMI trial randomly assigned 2571 patients with acute myocardial infarction (AMI) to receive influenza vaccine or saline placebo during their index hospital admission. It was conducted at 30 centers in 8 countries from October 1, 2016 to March 1, 2020. In this post-hoc exploratory sub-study, we compare the trial outcomes in patients receiving early season vaccination (n = 1188) and late season vaccination (n = 1344).The primary endpoint wasthe composite of all-cause death, myocardial infarction (MI), or stent thrombosis at 12 months. Thecumulative incidence of the primary and key secondary endpoints by randomized treatment and early or late vaccination was estimated using the Kaplan-Meier method. In the early vaccinated group, the primary composite endpoint occurred in 36 participants (6.0%) assigned to influenza vaccine and 49 (8.4%) assigned to placebo (HR 0.69; 95% CI 0.45 to 1.07), compared to 31 participants (4.7%) assigned to influenza vaccine and 42 (6.2%) assigned to placebo (HR 0.74; 95% CI 0.47 to 1.18) in the late vaccinated group (P = 0.848 for interaction on HR scale at 1 year). We observed similar estimates for the key secondary endpoints of all-cause death and CV death. There was no statistically significant difference in vaccine effectiveness against adverse cardiovascular events by timing of vaccination. The effect of vaccination on all-cause death at one year was more pronounced in the group receiving early vaccination (HR 0.50; 95% CI, 0.29 to 0.86) compared late vaccination group (HR 0.75; 35% CI, 0.40 to 1.40) but there was no statistically significant difference between these groups (Interaction P = 0.335). In conclusion,there is insufficient evidence from the trial to establish whether there is a difference in efficacy between early and late vaccinationbut regardless of vaccination timing we strongly recommend influenza vaccination in all patients with cardiovascular diseases.
- MeSH
- chřipka lidská * prevence a kontrola komplikace MeSH
- infarkt myokardu * MeSH
- lidé MeSH
- trombóza * MeSH
- vakcinace metody MeSH
- vakcíny proti chřipce * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Klíčová slova
- peramivir,
- MeSH
- analýza dat * MeSH
- antivirové látky farmakologie MeSH
- chřipka lidská * diagnóza epidemiologie komplikace prevence a kontrola MeSH
- lidé MeSH
- nemoci, jimž lze předcházet očkováním MeSH
- oseltamivir aplikace a dávkování terapeutické užití MeSH
- rizikové faktory MeSH
- vakcinace * statistika a číselné údaje MeSH
- vakcíny proti chřipce MeSH
- zanamivir aplikace a dávkování terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Geografické názvy
- Česká republika MeSH
- MeSH
- aktivní imunita imunologie MeSH
- chřipka lidská * epidemiologie komplikace mortalita prevence a kontrola MeSH
- kontraindikace léčebného výkonu MeSH
- lidé MeSH
- rizikové faktory MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- vakcinace * MeSH
- vakcinologie organizace a řízení MeSH
- vakcíny proti chřipce aplikace a dávkování klasifikace terapeutické užití MeSH
- věkové faktory MeSH
- Check Tag
- lidé MeSH
BACKGROUND: Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI. METHODS: A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020. Here we report vaccine effectiveness in the 2,467 participants with ST-segment elevation MI (STEMI, n = 1,348) or non-ST-segment elevation MI (NSTEMI, n = 1,119). The primary endpoint was the composite of all-cause death, MI, or stent thrombosis at 12 months. Cumulative incidence of the primary and key secondary endpoints by randomized treatment and NSTEMI/STEMI was estimated using the Kaplan-Meier method. Treatment effects were evaluated with formal interaction testing to assess for effect modification. RESULTS: Baseline risk was higher in participants with NSTEMI. In the NSTEMI group the primary endpoint occurred in 6.5% of participants assigned to influenza vaccine and 10.5% assigned to placebo (hazard ratio [HR], 0.60; 95% CI, 0.39-0.91), compared to 4.1% assigned to influenza vaccine and 4.5% assigned to placebo in the STEMI group (HR, 0.90; 95% CI, 0.54-1.50, P = .237 for interaction). Similar findings were seen for the key secondary endpoints of all-cause death and cardiovascular death. The Kaplan-Meier risk difference in all-cause death at one year was more pronounced in participants with NSTEMI (NSTEMI: HR, 0.47; 95% CI 0.28-0.80, STEMI: HR, 0.86; 95% CI, 0.43-1.70, interaction P = .028). CONCLUSIONS: The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI.
- MeSH
- chřipka lidská * komplikace prevence a kontrola MeSH
- infarkt myokardu bez ST elevací * komplikace MeSH
- infarkt myokardu s elevacemi ST úseků * terapie komplikace MeSH
- infarkt myokardu * komplikace MeSH
- lidé MeSH
- rizikové faktory MeSH
- vakcíny proti chřipce * MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
- MeSH
- chřipka lidská * dějiny diagnóza etiologie komplikace prevence a kontrola terapie MeSH
- lidé MeSH
- vakcíny proti chřipce klasifikace škodlivé účinky terapeutické užití MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
- Klíčová slova
- Efluelda,
- MeSH
- chřipka lidská diagnóza komplikace patofyziologie prevence a kontrola MeSH
- dospělí MeSH
- lidé MeSH
- vakcíny proti chřipce * aplikace a dávkování MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
- novinové články MeSH
Chřipka byla v České republice často vnímána jako běžné nekomplikované onemocnění. V poslední době zůstala zcela ve stínu nemoci covid-19, ale tato situace se může rychle změnit. Výskyt chřipky stoupá a dochází již běžně k paralelní cirkulaci viru SARS-CoV-2 a influenza virů. Na důležitosti tak opět nabývá očkování proti chřipce, které snižuje riziko nákazy a riziko komplikovaného průběhu. Očkované by měly být především osoby starší 65 let, pacienti s chronickými interními onemocněními (i v dětském věku), těhotné ženy a ti, kdo jsou s rizikovými osobami v kontaktu.
In the Czech Republic, influenza was often perceived as a common uncomplicated illness. Recently, it has been completely overshadowed by the covid-19 disease, but this situation can change quickly. The incidence of influenza is increasing, and parallel circulation of the SARS-CoV-2 virus and influenza viruses is now common. Vaccination against the flu, which reduces the risk of infection and the risk of a complicated course, is becoming more important. People over the age of 65, patients with chronic internal diseases (even in childhood), pregnant women and those who are in contact with risk persons should be vaccinated.
- MeSH
- chřipka lidská * komplikace prevence a kontrola MeSH
- COVID-19 MeSH
- dítě MeSH
- lidé MeSH
- vakcinace MeSH
- vakcíny proti chřipce MeSH
- Check Tag
- dítě MeSH
- lidé MeSH
- Publikační typ
- přehledy MeSH
